Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | SPR | P35270 | 2/20 | 0.31 |
| ▸ | NMT1 | P30419 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13106296 | 0.85 | ADORA2A (0.44) | ADORA2AADORA2BPIM3PIM2SPR | |
| SCHEMBL13106248 | 0.83 | ADORA2A (0.42) | ADORA2AADORA2BPIM3PIM2NMT1 | |
| SCHEMBL13106303 | 0.81 | ADORA2A (0.41) | ADORA2AADORA2BNMT1 | |
| SCHEMBL20356344 | 0.79 | ADORA3 (0.34) | — | |
| SCHEMBL13106364 | 0.79 | GAA (0.36) | — | |
| SCHEMBL19250513 | 0.78 | ADORA2A (0.51) | ADORA2AADORA2B | |
| SCHEMBL13106267 | 0.77 | ADORA2A (0.44) | ADORA2AADORA2BPIM3PIM2NMT1 | |
| SCHEMBL13106197 | 0.77 | ADORA2A (0.44) | ADORA2AADORA2BPIM3PIM2SPR | |
| SCHEMBL13106292 | 0.75 | CHEK1 (0.51) | ADORA2AADORA2B | |
| SCHEMBL20674107 | 0.74 | PIM3 (0.48) | ADORA2AADORA2BPIM3PIM2SPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812045-B2 | Antifungal triazole derivatives | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2010-10-12 | — | — | US | disclosed |
| US-20080194661-A1 | Antifungal Triazole Derivatives | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194661-A1 | Antifungal Triazole Derivatives | ERG28, CYP51A1, CYP3A43 | ADORA2A 3466/4885ADORA2B 3798/4885PIM3 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.